Jcar-017 Cd19-Specific Chimeric Antigen Receptor
Immunoproliferative Disorder
Explore 10 assets in Immunoproliferative Disorder →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Juno Therapeutics, a Subsidiary of Celgene
Modality
Cell therapy
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03744676CT.gov A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Immunoproliferative Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Jcar-017 Cd19-Specific Chimeric Antigen Receptor (this asset) | Juno Therapeutics, a Subsidiary of Celgene | P2 | B · 57 |
| Zilovertamab | Oncternal Therapeutics, Inc | P3 | B |
| Ibrutinib | Oncternal Therapeutics, Inc | P3 | B |
| Tucidinostat | Fudan University | P2 | CCC |
| Atlcar.Cd30.Ccr4 Cells | UNC Lineberger Comprehensive Cancer Center | P1 | CC |
| Cyclophosphamide | UNC Lineberger Comprehensive Cancer Center | P1 | CC |
| Oricar-017 | OriCell Therapeutics Co., Ltd. | P1 | CC |
| Kln-1010 | Kelonia Therapeutics, Inc. | P1 | CC |
| Bendamustine | UNC Lineberger Comprehensive Cancer Center | P1 | CC |
+4 more in the Immunoproliferative Disorder cohort
Other indications for Jcar-017 Cd19-Specific Chimeric Antigen Receptor
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Diffuse Large B-Cell Lymphoma | — | P3 | BB · 66 |
| Primary Mediastinal Large B-Cell Lymphoma | — | P2 | BB · 65 |
| Non-Hodgkin Lymphoma | — | P3 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Jcar-017 Cd19-Specific Chimeric Antigen Receptor in Immunoproliferative Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/jcar-017-cd19-specific-chimeric-antigen-receptor-immunoproliferative-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →